US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-4)
Latest Information Update: 13 Nov 2026
At a glance
- Drugs Fasedienol (Primary)
- Indications Social phobia
- Focus Registrational; Therapeutic Use
- Acronyms PALISADE-4
- Sponsors VistaGen Therapeutics
Most Recent Events
- 04 Nov 2026 Status changed from active, no longer recruiting to completed.
- 24 Sep 2026 Primary endpoint(Subjective Units of Distress Scale (SUDS)) has not been met.
- 22 Sep 2026 Results presented in a Vistagen Media Release.